Metabolic•Exercise Mimetic
⚖️MOTS-C
Mitochondria-encoded exercise mimetic peptide. Activates AMPK via AICAR, improves insulin sensitivity and drives fat oxidation — independently of insulin receptor signalling.
Amino acids
16
Mol. weight
2174.5 Da
Half-life
1–2 hours (SC)
Availability
In stock
Amino acid sequence
MRWQEMGYIFYPRKLRWhat Is MOTS-C?
MOTS-C (Mitochondrial Open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — not the nuclear genome. Discovered in 2015 by Lee et al. at USC, it is a founding member of mitochondrial-derived peptides (MDPs). Its plasma levels decline with age and obesity, inversely correlating with insulin resistance and metabolic syndrome.
Key Mechanisms
- AMPK activation via AICAR — inhibits MTHFD1 in the folate cycle, accumulating AICAR (endogenous AMP-mimetic) that phosphorylates AMPK at Thr172
- Nuclear retrograde signalling — translocates to nucleus under stress to modify ARE/Nrf2 gene expression
- GLUT4 translocation — drives skeletal muscle glucose uptake independently of insulin receptor
- β-Oxidation enhancement — AMPK→ACC inhibition→CPT-1 relief→increased mitochondrial fat import
- mTORC1 suppression — via TSC2/Raptor phosphorylation — longevity-associated metabolic state
Research Applications
- Metabolic syndrome and obesity biology
- Exercise adaptation and skeletal muscle metabolism
- Insulin resistance mechanisms
- Aging and healthspan research
- Mitochondrial biology and retrograde signalling
Key References
- Lee C et al. "MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab, 2015;21(3):443–454.
- Reynolds JC et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator." Nat Commun, 2021;12:470.
Related in Metabolic
⚖️Phase II Champion
Retatrutide (LY3437943)
Triple GIP/GLP-1/glucagon receptor agonist. Phase II trial demonstrated 24.2% body weight reduction at 48 weeks — the highest ever recorded for a pharmacological agent.
⚖️GLP-1 Agonist
Semaglutide
GLP-1 receptor agonist. FDA-approved (Ozempic/Wegovy). Up to 15% weight loss in Phase III trials. Reduces cardiovascular events (SELECT trial). The benchmark for GLP-1 weight loss research.
⚖️Dual Agonist
Tirzepatide
FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound). Up to 22.5% weight loss in SURMOUNT-1 trial. Currently the most effective approved anti-obesity medication.
